RxDoctor Payments Data

Constantine Boiangiu, MD

Cardiovascular Disease · Tucson, AZNPI 1265645436

Payments from drug & device makers

$4,138in general payments, 2019–2025

Across 198 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$790
  • Novartis$642
  • Abbott$327
  • Abiomed$289
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$271
  • Kestra Medical Technology Services, Inc.$256
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$76218%
  • Food & beverage$3,34081%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,138 in reported general payments places this provider in the 55th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$1,147,270
Medicare patients
1,149
Services billed
6,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$245,173
EntrestoSacubitril/Valsartan93$141,218
JardianceEmpagliflozin80$109,435
Repatha SureclickEvolocumab89$76,424
VascepaIcosapent Ethyl44$37,167
BrilintaTicagrelor41$29,755
Ezetimibe861$21,727
XareltoRivaroxaban14$19,988
NexletolBempedoic Acid19$19,885
FarxigaDapagliflozin Propanediol13$18,870
LivaloPitavastatin Calcium34$17,068
Flecainide Acetate163$6,278
Rosuvastatin Calcium644$5,640
Icosapent Ethyl14$3,892
Metoprolol Succinate299$3,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$245,173208 claims
NovartisEntresto$642$141,21893 claims
Boehringer IngelheimJardiance$104$109,43580 claims
AstraZenecaBrilinta, Farxiga$203$48,62554 claims
Johnson & JohnsonXarelto$16$19,98814 claims
Esperion Therapeutics, Inc.Nexletol$39$19,88519 claims
Kowa Pharmaceuticals America, Inc.Livalo$203$17,06834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →